The shadow of generic challenges has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the future of connected drug holdings. While early times saw impressive returns, the exclusivity expiration has opened the door for less expensive alternatives, likely diminishing earnings and posing a real danger for